DFX Intelligence

Data Factory

ATHOS

Family Offices

Holzkirchen

ATHOS invests entrepreneurially and value-based with a focus on Pharma and Life Science

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:be40f1ce-ee3e-4748-ad44-58572884610d

Data as of Sep 16, 2026 (this record's last observation) from dfx's own graph. Page built Sep 19, 2026, 8:02 AM UTC and rebuilt at most every 15 minutes.

Relationships: 47
Dated events: 9
On other graphs: 0
Observed: Sep 14, 2026 to Sep 16, 2026
20 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Wealth origin: Wealth from sale of pharmaceutical company Hexal to Novartis in 2005 for $6.7 billion
Invests directly: ATHOS invests directly in companies with a long-term, entrepreneurial technology focus
Sectors: Healthcare and life sciences focus
Investments: 5
Direct investments: 5
Latest investment: Nov 3, 2025
People: 4
Decision makers: 2derived

Investments

Target	State	Kind	Asset class	Sector	Announced	Amount	Evidence
AAVantgarde	n/a	Round participation	n/a	n/a	Nov 3, 2025	n/a	fact
AAVantgarde Bio	n/a	Series B	biotechnology	gene therapy	Nov 3, 2025	n/a	fact
Formycon AG	n/a	equity stake / asset acquisition	biotechnology	biosimilars	May 10, 2022	n/a	fact
Conergy	n/a	capital increase underwriting	renewable energy	solar	Jan 1, 2008	n/a	fact
BioNTech SE	n/a	anchor equity investment	biotechnology	mRNA/oncology	Jan 1, 2008	n/a	fact

People

Person	Title	Role	Seniority	Family member	Current	Evidence
Andreas Strüngmann	Principal	Family principal	senior	yes	yes	fact
Thomas Strüngmann	Principal	Family principal	senior	yes	yes	fact
Helmut Jeggle	General Partner (Komplementär)	leadership	senior	no	yes	fact
Thomas Maier	General Partner (Komplementär)	leadership	senior	no	yes	fact

Relationships

Invested in (5)

→ ConergyCompanycapital increase underwriting
Jan 1, 2008 to presentfactDFX's own graph
→ AAVantgarde BioCompanySeries B
Nov 3, 2025 to presentfactDFX's own graph
→ Formycon AGCompanyequity stake / asset acquisition
May 10, 2022 to presentfactDFX's own graph
→ BioNTech SECompanyanchor equity investment
Jan 1, 2008 to presentfactDFX's own graph
→ AAVantgardeCompanyRound participation
Nov 3, 2025 to presentfactNews and newswire

Co invested with (14)

→ Sofinnova PartnersOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Longwood FundOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Willett AdvisorsOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ XGen VentureOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph, News and newswire
→ Sixty Degree CapitalOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph, News and newswire
→ Neva SGROrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph, News and newswire
→ Columbia IMCOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph, News and newswire
→ CDP Venture CapitalOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Amgen VenturesOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph, News and newswire
→ ForbionOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Atlas VentureOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Schroders CapitalOrgAAVantgarde Bio
Nov 3, 2025 to presentfactDFX's own graph
→ Willett AdvisorsOfficeAAVantgarde
Nov 3, 2025 to presentfactNews and newswire
→ CDP Venture Capital through its Large Ventures FundOrgAAVantgarde
Nov 3, 2025 to presentfactNews and newswire

Employs (4)

→ Thomas MaierPersonGeneral Partner (Komplementär)
factDFX's own graph
→ Helmut JegglePersonGeneral Partner (Komplementär)
factDFX's own graph
→ Andreas StrüngmannPersonPrincipal
factDFX's own graph
→ Thomas StrüngmannPersonPrincipal
factDFX's own graph

Dated events

2 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Nov 3, 2025
Direct investment announced
ATHOS invested in AAVantgarde Bio
AAVantgarde Bio DFX's own graphobserved 3 days ago
Occurred
Nov 3, 2025
Direct investment announced
ATHOS joins AAVantgarde Bio's $141M Series B financing
DFX's own graphobserved 3 days ago
Occurred
May 10, 2022
Direct investment announced
ATHOS invested in Formycon AG
Formycon AG DFX's own graphobserved 3 days ago
Occurred
May 10, 2022
Direct investment announced
ATHOS becomes Formycon's largest shareholder via biosimilar asset deal
DFX's own graphobserved 3 days ago
Occurred
Jan 1, 2008
Direct investment announced
ATHOS invested in BioNTech SE
BioNTech SE DFX's own graphobserved 3 days ago
Occurred
Jan 1, 2008
Direct investment announced
ATHOS invested in Conergy
Conergy DFX's own graphobserved 3 days ago
Occurred
Feb 21, 2005
Family liquidity event
Strüngmann brothers sell Hexal AG and Eon Labs stake to Novartis
DFX's own graphobserved 3 days ago

Show 2 bookkeeping events

First seen by DFX
Sep 15, 2026
date not stated
ATHOS: PROBABLE_SFO -> CONFIRMED_SFO (Wikipedia, independent of the GlobeNewswire AAVantgarde source, confirms Athos KG is the single family office of twin brothers Thomas and Andreas Strüngmann, who built and sold the pharmaceutical company Hexal.)
Occurred
Nov 3, 2025
ATHOS named as a single family office on globenewswire

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

Also named here, with no published line of their own (reach them through the firm): Thomas Maier (General Partner (Komplementär)), Helmut Jeggle (General Partner (Komplementär)), Andreas Strüngmann (Principal), Thomas Strüngmann (Principal).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Family Offices
Canonical id: dfx:fo:be40f1ce-ee3e-4748-ad44-58572884610d
First observed: Sep 14, 2026
Last observed: Sep 16, 2026 2 days ago
Source families: DFX's own graph
2 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

ATHOS

Family Offices

Holzkirchen

ATHOS invests entrepreneurially and value-based with a focus on Pharma and Life Science

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:be40f1ce-ee3e-4748-ad44-58572884610d

Data as of Sep 16, 2026 (this record's last observation) from dfx's own graph. Page built Sep 19, 2026, 8:02 AM UTC and rebuilt at most every 15 minutes.

Target

State

Kind

Asset class

Sector

Announced

Amount

Evidence

AAVantgarde

n/a

Round participation

n/a

Nov 3, 2025

n/a

fact

AAVantgarde Bio

n/a

Series B

biotechnology

gene therapy

Nov 3, 2025

n/a

fact

Formycon AG

n/a

equity stake / asset acquisition

biotechnology

biosimilars

May 10, 2022

n/a

fact

Conergy

n/a

capital increase underwriting

renewable energy

solar

Jan 1, 2008

n/a

fact

BioNTech SE

n/a

anchor equity investment

biotechnology

mRNA/oncology

Jan 1, 2008

n/a

fact

Person

Title

Role

Seniority

Family member

Current

Evidence

Andreas Strüngmann

Principal

Family principal

senior

yes

fact

Thomas Strüngmann

Principal

Family principal

senior

yes

fact

Helmut Jeggle

General Partner (Komplementär)

leadership

senior

yes

fact

Thomas Maier

General Partner (Komplementär)

leadership

senior

yes

fact